Brilacidin has almost zero absorption through mucosal and gastric tissues. This was established in early trials for colitis and oral mucositis. At the time it was viewed as a benefit because treatment did not include any of the circulatory organs, which means that treatment against oral/digestive diseases does not have to consider impact on the liver or kidneys or the liver processes on the drug.
However, that also means that using Brilacidin to treat respiratory and pulmonary organs cannot be administered orally. It must be administered via injection or inhalation. The drug already has been thoroughly tested administered IV. To be inhaled it would need to go through preclinical work for the best method and formulation (expansive and time consuming).
One doesn’t have to be Dr. DeGrado to know these things.
News 
Market Data 
Discover 
